VitaLonga

Human study · Aging · 18 Nov 2026

In 514 people, a blood p-tau217 test matched spinal-fluid tests for amyloid plaques

Source: Nature Aging

What the research found

A diagnostic comparison in Alzheimer's disease was published online on 18 November 2026. It covered 514 people: a memory clinic (129), primary care (220), and a research cohort (165). The abstract does not give ages or a sex split. Lumipulse plasma p-tau217, and the ratio of p-tau217 to amyloid-beta 42, were compared with authorized spinal-fluid tests for amyloid plaques on a PET scan. Areas under the curve were 0.90 to 0.96. With one cutoff, accuracy was 83 to 91 percent for plasma p-tau217 and 83 to 92 percent for the ratio, against 88 to 90 percent for spinal fluid (all p at least 0.05). With two cutoffs, plasma p-tau217 accuracy was 90 to 97 percent, against 91 percent for spinal fluid in the clinical cohorts (adjusted p at least 0.12). The paper says this was in people who already had symptoms. A blood test compared with scans, not a treatment. DOI 10.1038/s43587-026-01259-z. Not medical advice.

Evidence level: Human study. A study in people, but an association isn't proof of cause.

Read the original at Nature Aging

More aging news